RxDoctor Payments Data

Michael Shirk, MD

Family Medicine · Lancaster, PANPI 1174548820

Payments from drug & device makers

$486in general payments, 2019–2025

Across 11 payments — averaging $44.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$250
  • Sanofi-aventis U.S. LLC$122
  • AstraZeneca$37
  • Novo Nordisk$36
  • Johnson & Johnson$16
  • Lilly USA, LLC$13
  • plus $12 from 1 others

What the payments were for

  • Speaking & faculty fees$37277%
  • Food & beverage$10221%
  • Education$122%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$486 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$281,836
Medicare patients
483
Services billed
3,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$216,665
EliquisApixaban232$203,932
JardianceEmpagliflozin179$197,218
TrulicityDulaglutide62$84,807
JanuviaSitagliptin Phosphate62$79,103
XareltoRivaroxaban59$62,236
MounjaroTirzepatide34$34,518
Tresiba Flextouch U-100Insulin Degludec54$33,231
JanumetSitagliptin Phos/Metformin Hcl22$31,155
Breo ElliptaFluticasone/Vilanterol47$24,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,961
NucyntaTapentadol Hcl50$17,887
Atorvastatin Calcium1,206$11,421
Spiriva HandihalerTiotropium Bromide19$9,557
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$216,665200 claims
Lilly USA, LLCTrulicity, Mounjaro$13$119,32596 claims
MerckJanuvia, Janumet$12$110,25884 claims
Johnson & JohnsonXarelto$16$62,23659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →